​

Generation Bio (GBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

GBIO Stock Rating

Generation Bio stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (50.00%), 5 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 5 5 Strong Sell Sell Hold Buy Strong Buy

GBIO Price Target Upside V Benchmarks

TypeNameUpside
StockGeneration Bio-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$5.80$5.80$5.80
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25123--6
Sep, 25123--6
Aug, 25132--6
Jul, 25133--7
Jun, 25133--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 13, 2025WedbushNeutraldowngrade
Mar 06, 2023JMP SecuritiesMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.96$-1.98----
Avg Forecast$-0.75$-1.95$-1.08$-0.92$-0.88$-0.84
High Forecast$0.36$-1.27$-0.35$-0.17$-0.69$0.16
Low Forecast$-1.85$-2.25$-1.34$-1.26$-1.01$-2.22
Surprise %161.33%1.54%----

Revenue Forecast

$0 $5M $10M $15M $20M $25M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.90M$19.89M----
Avg Forecast$4.10M$18.14M$7.11M$7.82M$8.30M$8.10M
High Forecast$5.46M$21.50M$16.18M$7.82M$18.90M$18.44M
Low Forecast$2.72M$14.71M$597.30K$7.82M$697.56K$680.67K
Surprise %44.08%9.67%----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-126.61M$-131.67M----
Avg Forecast$-48.25M$-113.66M$-79.08M$-80.66M$-54.70M$-53.84M
High Forecast$22.91M$-82.01M$-22.65M$-11.06M$-44.35M$10.27M
Low Forecast$-119.41M$-145.32M$-86.20M$-81.38M$-65.05M$-143.18M
Surprise %162.40%15.84%----

GBIO Forecast FAQ

Is Generation Bio stock a buy?

Generation Bio stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Generation Bio is a favorable investment for most analysts.

What is Generation Bio's price target?

Generation Bio's price target, set by 10 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $5.8.

How does Generation Bio stock forecast compare to its benchmarks?

Generation Bio's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Generation Bio over the past three months?

  • October 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 16.67% Strong Buy, 50.00% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Generation Bio’s EPS forecast?

Generation Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.08, marking a -45.45% decrease from the reported $-1.98 in 2024. Estimates for the following years are $-0.92 in 2026, $-0.88 in 2027, and $-0.84 in 2028.

What is Generation Bio’s revenue forecast?

Generation Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $7.11M, reflecting a -64.27% decrease from the reported $19.89M in 2024. The forecast for 2026 is $7.82M, followed by $8.3M for 2027, and $8.1M for 2028.

What is Generation Bio’s net income forecast?

Generation Bio's net income forecast for the fiscal year ending in December 2025 stands at $-79.075M, representing a -39.94% decrease from the reported $-132M in 2024. Projections indicate $-80.656M in 2026, $-54.701M in 2027, and $-53.844M in 2028.